Detalhe da pesquisa
1.
Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab.
Blood
; 134(10): 814-825, 2019 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31270105
2.
CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
Int J Hematol
; 108(1): 47-57, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29600428